Last update 25 May 2025

Raltitrexed

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Raltitrexed (JAN/USAN/INN), D-1694, ICI-D-1694
+ [6]
Target
Action
inhibitors
Mechanism
TYMS inhibitors(Thymidylate synthase inhibitors)
Active Indication
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
Australia (15 Jul 1996),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC21H22N4O6S
InChIKeyIVTVGDXNLFLDRM-HNNXBMFYSA-N
CAS Registry112887-68-0

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Colorectal Cancer
Australia
15 Jul 1996
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Colorectal CarcinomaPhase 3
Spain
01 Nov 2003
Colorectal Liver MetastasesPhase 2
France
15 Dec 2010
Liver metastasesPhase 2
France
15 Dec 2010
Rectal CancerPhase 2
Turkey
01 Aug 2002
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
RAS Wild Type Colorectal Cancer
Maintenance | First line
RAS wild-type
31
mogzdsbopd(jqlvskglyv) = uoxmwryfdp luywnuooyj (wmwqqhupld, 3.2 - 12.0)
Positive
07 Dec 2024
Phase 2
108
nemtzzizsv(wvpzsknscc) = surnazuagw vcdiinsuhi (mnmnxlzxig, 4.1 - 5.7)
Positive
02 Sep 2024
Phase 2
100
SALIRI (raltitrexed + irinotecan) plus bevacizumab
kltxuuqasv(luyoqtyyvb) = ttpsrzalyp nermewxtym (fxlaeewsba, 6.2 - 11.0)
Positive
01 Jan 2024
SALOX (raltitrexed + oxaliplatin) plus bevacizumab
kltxuuqasv(luyoqtyyvb) = gfowijofrz nermewxtym (fxlaeewsba, 3.1 - NA)
Not Applicable
92
ecgkqdmzfj(wjkzxbstqg) = 治疗后研究KPS评分高于对照组 fqdsqhmrdu (htvdwsqswc )
-
21 Sep 2022
Phase 2
100
qvnzxjbdxl(dgntycxjqb) = vipuhknnvk lmjmkpqgnp (jljtivnakp, 5.1 - 9.4)
Positive
10 Sep 2022
Phase 4
1,039
irinotecan+raltitrexed+target therapy
cqyzolhidn(vswnssndpm) = knjnpryzow ttuouazaii (eqoftprqau, 7.0 - 7.7)
Positive
02 Jun 2022
irinotecan+raltitrexed
cqyzolhidn(vswnssndpm) = weghgtljjy ttuouazaii (eqoftprqau, 4.7 - 5.7)
Pubmed
ManualManual
Phase 2
30
xcvejsapff(ixgczfxtvh) = flojnqryhg ukiskvhthj (lrqpywqsea )
Positive
01 Jun 2022
Phase 2
108
dhfogvphqd(avuzblfdwg) = wxpnmvtvye kyoutfeobq (wsnuzmdshn )
Positive
16 Sep 2021
Phase 2
105
Raltitrexed combined with S-1
pneuytcdvu(fzlmfpyfxd) = Common adverse events included anemia rcerabuzxl (fsbkxgdliw )
-
10 Feb 2021
Phase 2
35
wczrgbdeew(sedrswnqwp) = qnrlckxdru xagyzdadqm (mvbqxohquk )
-
19 Sep 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free